- Home
- MCRB vs CHN Comparison
MCRB vs CHN Comparison
Compare MCRB & CHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- CHN
- Stock Information
- Founded
- MCRB 2010
- CHN 1992
- Country
- MCRB United States
- CHN United States
- Employees
- MCRB N/A
- CHN N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- CHN Investment Managers
- Sector
- MCRB Health Care
- CHN Finance
- Exchange
- MCRB Nasdaq
- CHN Nasdaq
- Market Cap
- MCRB 156.3M
- CHN 118.5M
- IPO Year
- MCRB 2015
- CHN N/A
- Fundamental
- Price
- MCRB $0.84
- CHN $11.64
- Analyst Decision
- MCRB Buy
- CHN
- Analyst Count
- MCRB 4
- CHN 0
- Target Price
- MCRB $5.63
- CHN N/A
- AVG Volume (30 Days)
- MCRB 2.4M
- CHN 31.8K
- Earning Date
- MCRB 11-13-2024
- CHN 01-01-0001
- Dividend Yield
- MCRB N/A
- CHN 0.19%
- EPS Growth
- MCRB N/A
- CHN N/A
- EPS
- MCRB N/A
- CHN N/A
- Revenue
- MCRB $126,325,000.00
- CHN N/A
- Revenue This Year
- MCRB N/A
- CHN N/A
- Revenue Next Year
- MCRB N/A
- CHN N/A
- P/E Ratio
- MCRB N/A
- CHN N/A
- Revenue Growth
- MCRB 12856.41
- CHN N/A
- 52 Week Low
- MCRB $0.54
- CHN $9.00
- 52 Week High
- MCRB $2.05
- CHN $12.98
- Technical
- Relative Strength Index (RSI)
- MCRB 47.60
- CHN 40.11
- Support Level
- MCRB $0.80
- CHN $11.88
- Resistance Level
- MCRB $1.00
- CHN $12.35
- Average True Range (ATR)
- MCRB 0.06
- CHN 0.36
- MACD
- MCRB -0.01
- CHN -0.04
- Stochastic Oscillator
- MCRB 20.46
- CHN 4.96
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants and Leisure among others.